Myeloma

Five years from now multiple myeloma will have a therapeutic backbone consisting entirely of combinations of novel agents, a leading myeloma researcher predicts.

C. Ola Landgren provides an overview of the diagnosis and treatment of smoldering multiple myeloma.

C. Ola Landgren discusses ways to measure response to treatment in multiple myeloma.

A combination approach can improve responses through mechanisms that, "enhance immune function, enhance receptor expression, or target intracellular signaling."

By donating stem cells through Be The Match, healthy adults can save the lives of people with blood cancers.

The agent gained a priority review designation for use in combination with dexamethasone for patients with relapsed multiple myeloma following prior treatment with at least one therapy, based on findings from the phase 3 ENDEAVOR trial.

After stem cell transplants for blood cancers, patients -- with help from their caregivers -- must be careful to avoid infections.

With new treatments transforming multiple myeloma into a chronic condition and additional therapies on the horizon, some experts believe a cure is within view.

There are several agents available for patients who experience recurrence, Kumar says, though nearly all of them have the potential to move to an earlier setting.

Shaji Kumar, professor of medicine, Division of Hematology, Mayo Clinic, discusses common treatment-related adverse events from monoclonal antibodies in patients with multiple myeloma.

Adding elotuzumab to Revlimid (lenalidomide) and dexamethasone reduced the risk of disease progression by 30 percent in patients with relapsed/refractory multiple myeloma.

A navigator-designed, proactive, weekly, telephone support call to help patients with blood cancers manage their symptoms between appointments was able to significantly reduce unplanned hospitalizations at a Colorado cancer center.

Jasmine Martin, Director, West Region Medical Science Liaison Team, Takeda Oncology, discusses oral adherence.

Sandra Spoelstra, PhD, RN, Assistant Professor, College of Nursing, Michigan State University, discusses educating patients about oral agents.

Amanda Yopp, NP, Clinical Nurse Educator, Takeda Oncology, discusses educating patients before they enroll on a clinic trial.

Investigational monoclonal antibodies, such as daratumumab and elotuzumab, could potentially change the role of stem cell transplantation for patients with multiple myeloma.

Kyprolis doubled progression-free survival versus Velcade in patients with relapsed multiple myeloma in the phase 3 ENDEAVOR trial.

The FDA has approved Farydak (panobinostat) in combination with Velcade (bortezomib) and dexamethasone for patients with multiple myeloma who receive prior treatment with Velcade and an immunomodulatory (IMiD) agent, based on results of the PANORAMA-1 trial.

Lauren Hill, a student-athlete at Mount St. Joseph University, has inspired many with her commitment to fulfilling her dream of playing college basketball despite a diagnosis of diffuse intrinsic pontine glioma (DIPG), an aggressive type of brain tumor.

The FDA has approved Revlimid plus dexamethasone in newly diagnosed patients with multiple myeloma based on findings from the phase 3 FIRST trial.

Ixazomib, also known as MLN9708, met its primary endpoint of improving progression-free survival at an interim analysis of a phase 3 trial of relapsed or refractory multiple myeloma.

Anne Quinn Young, of the Multiple Myeloma Research Foundation, discusses some of the antibodies that are being studied in multiple myeloma.

Brian G.M. Durie, an expert in multiple myeloma at Cedars-Sinai in Los Angeles, Calif., and chairman of the International Myeloma Foundation, discusses the ASPIRE trial for patients with relapsed myeloma.

The Food and Drug Administration's calendar for making decisions on new cancer drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.

Anne Young Quinn, of the MMRF, explains the catalyst behind the CoMMpass study and how it may be changing the future of myeloma treatment.